Advances in Leukemia adheres to rigorous editorial policies to ensure integrity, transparency, and clinical relevance.

All submissions undergo editorial screening and expert peer review. Decisions are based on scientific merit and scope fit.

Ethics approvals, consent documentation, and conflict disclosures are required for all applicable studies.

Submissions undergo similarity checks and may receive statistical review when warranted.

Data integrity concerns may require additional documentation.

Conflicts of interest must be disclosed for authors, reviewers, and editors.

Plagiarism screening is performed before peer review.

Clinical trials must be registered and include identifiers.

Data integrity concerns may trigger requests for raw data.

Corrections and retractions are issued transparently when needed.

Authorship disputes are handled in line with COPE guidance.

Image manipulation beyond standard adjustments is not permitted.

Data availability statements are required for all submissions.

Peer review identities are protected and handled confidentially.

Authors must disclose funding sources and sponsor roles.

Data fabrication or falsification results in rejection and notification.

Duplicate submissions are not permitted under journal policy.

Appeals are reviewed independently for fairness.

Confidentiality is maintained for all submissions and reviews.

Reporting guideline adherence is encouraged for all study types.

Data availability statements are required for transparency.

Ethics approvals must be documented in the manuscript.

Editors may request raw data for verification in exceptional cases.

Misconduct allegations are handled according to COPE processes.

Corrections are linked to original articles to preserve the record.

Clinical trial registration is required prior to patient enrollment.

Generative AI disclosures are required when used for language support.

Authors must confirm that submitted work is original and unpublished.

All submissions are handled with confidentiality throughout review.

Data sharing exceptions must be justified in the manuscript.

Ethical approvals are verified for human and animal studies.

Corrections and updates are clearly linked to original articles.

Editors may request clarifications for conflicts of interest disclosures.

Clinical trial results must follow recognized reporting standards.

Ethical approvals and consent must be documented in the manuscript.

All authors must meet contribution criteria for authorship.

Data sharing restrictions must be justified transparently.

Peer review decisions are based on scientific and clinical merit.

Editors adhere to confidentiality and conflict of interest policies.

Corrections are published when errors affect interpretation.

Retractions are issued when evidence of misconduct is confirmed.

Image screening may be applied to detect manipulation.

Statistical review may be requested for complex analyses.

Ethics statements must align with study location and scope.

Conflict disclosures should include financial and advisory roles.

Data access restrictions should be transparent and justified.

All manuscripts are handled with confidentiality and care.

We maintain clear procedures for handling author complaints.

Ethical compliance is reviewed at multiple stages of submission.

Any suspected misconduct is documented and investigated.

Data integrity checks protect the reliability of published results.

Conflicts of interest are reviewed during editorial screening.

Editorial actions follow documented policies for transparency.

Authors must confirm originality and avoid duplicate submission.

Ethics approvals are checked before peer review begins.

All decision outcomes are documented for audit purposes.

Ethics statements should include consent procedures when applicable.

Policies support transparency in funding and conflict disclosures.

All manuscripts are evaluated with clinical relevance in mind.

Policy adherence strengthens trust in published leukemia research.

Clinical trials must be registered and include registry identifiers.

Generative AI tools may be used for language support but must be disclosed and cannot be credited as authors.

Corrections and retractions are issued transparently when required to protect the scholarly record.